Advertisement
Advertisement
U.S. markets open in 3 hours 36 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Seagen Inc. (SGEN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
139.17+1.47 (+1.07%)
At close: 04:00PM EDT
138.00 -1.17 (-0.84%)
After hours: 07:58PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close137.70
Open138.53
Bid0.00 x 800
Ask0.00 x 1100
Day's Range137.75 - 139.96
52 Week Range105.43 - 192.79
Volume820,165
Avg. Volume1,066,043
Market Cap25.506B
Beta (5Y Monthly)0.62
PE Ratio (TTM)N/A
EPS (TTM)-3.78
Earnings DateOct 26, 2022 - Oct 31, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est185.10
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for SGEN

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Seagen Inc.
    Analyst Report: Seagen Inc.Seagen (formerly known as Seattle Genetics) is a biotech firm that develops and commercializes therapies to treat cancers. Seagen’s therapies are based on antibody-drug conjugate technology that utilizes the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. The company's lead product, Adcetris, has received approval for six indications to treat Hodgkin lymphoma and T-cell lymphoma. Other approved products include Padcev for bladder cancer, Tukysa for breast cancer, and Tivdak for cervical cancer. The company has several other oncology programs in pivotal trials. Seagen also licenses its antibody-drug conjugate technology to several leading biotechnology and pharmaceutical companies.
    Rating
    Fair Value
    Economic Moat
    6 days agoMorningstar
View more
Advertisement
Advertisement